近肾及肾旁腹主动脉瘤开窗/分支支架腔内修复术后II型内漏
该研究前瞻性收集2016至2022年接受开窗/分支支架腔内修复(F/B-EVAR)的近肾及肾旁腹主动脉瘤(J/P-AAAs)患者并回顾性分析,报告持续性II型内漏(pEL2)的发生率、危险因素及自然史。132例中pEL2发生率为26%(28/107),术前抗血小板治疗、瘤内血栓体积≤40%及≥6条通畅的瘤囊传入血管为独立危险因素;pEL2与动脉瘤未缩小独立相关(HR 3.2),未缩小者随访生存率及免于再干预率更低。
要点
- F/B-EVAR治疗J/P-AAAs后pEL2发生率为26%(28/107例有≥6个月影像随访者)。
- 术前抗血小板治疗、瘤内血栓体积≤40%及≥6条通畅瘤囊传入血管为pEL2独立危险因素。
- pEL2与随访期间动脉瘤未缩小独立相关(HR 3.2,95%CI 1.2-8.3,P=.014)。
核心结论
- pEL2在F/B-EVAR治疗J/P-AAAs后并不少见(26%),与术前抗血小板治疗、瘤内血栓体积≤40%及≥6条通畅瘤囊传入血管相关。
- pEL2患者动脉瘤缩小减少,而动脉瘤缩小与更高的随访生存率和免于再干预率相关。
研究设计与样本
- 2016年至2022年前瞻性收集所有接受F/B-EVAR的J/P-AAAs患者并进行回顾性分析。
- 共纳入132例患者,其中近肾腹主动脉瘤88例(67%),肾旁腹主动脉瘤44例(33%)。
- 主要结局为完成造影、30天及6个月后评估的EL2;次要结局包括pEL2的术前危险因素、随访生存、免于再干预(FFR)及动脉瘤缩小(≥5 mm)。
主要发现
- 完成造影时检出17例EL2(13%),30天CTA检出36例(27%)。
- 平均随访28±23个月;11例(31%)EL2在6个月内自愈,新发3例,在有≥6个月影像随访的107例患者中总体pEL2为28例(26%)。
- 术前抗血小板治疗(OR 4.7,95%CI 1-22.1,P=.05)、瘤内血栓体积≤40%及≥6条通畅瘤囊传入血管(OR 7.2,95%CI 1.8-29.1,P=.005)为pEL2独立危险因素。
- 估计3年生存率为80%,有无pEL2者无差异(78% vs 85%,P=.08);估计3年FFR为86%,有无pEL2者无差异(81% vs 87%,P=.41)。
- 发生4例(3%)EL2相关再干预;65例(49%)检出动脉瘤缩小;pEL2为随访期间动脉瘤未缩小的独立危险因素(HR 3.2,95%CI 1.2-8.3,P=.014);未缩小者3年随访生存率(64% vs 86%,P=.009)和FFR(74% vs 90%,P=.014)低于缩小者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Persistent type II endoleaks (pEL2s) are not uncommon after endovascular aneurysm repair and their impact on long-term outcomes is well-documented. However, their occurrence and natural history after fenestrated/branched endografting (F/B-EVAR) for juxtarenal and pararenal aneurysms (J/P-AAAs) have been scarcely investigated. Aim of this study was to report incidence, risk factors, and natural history of pEL2 after F/B-EVAR in J/P-AAAs. METHODS: Between 2016 and 2022, all J/P-AAAs undergoing F/B-EVAR were prospectively collected and retrospectively analyzed. EL2 were assessed at the completion angiography, at 30 days and after 6 months as primary outcomes. Preoperative risk factors for pEL2, follow-up survival, freedom from reinterventions (FFR) and aneurysm shrinkage (≥5 mm) were considered as secondary outcomes. RESULTS: Of 132 patients, there were 88 (67%) JAAAs and 44 (33%) PAAAs. Seventeen EL2 (13%) were detected at the completion angiography and 36 (27%) at 30-day computed tomography angiography. The mean follow-up was 28 ± 23 months. Eleven (31%) EL2 sealed spontaneously within 6 months and three new cases were detected, for an overall of 28 pEL2/107 patients (26%) with available radiological follow-up of ≥6 months. Preoperative antiplatelet therapy (odds ratio, 4.7; 95% confidence interval [CI[, 1-22.1; P = .05), aneurysm thrombus volume of ≤40% and six or more patent aneurysm afferent vessels (odds ratio, 7.2; 95% CI, 1.8-29.1; P = .005) were independent risk factors for pEL2. The estimated 3-year survival was 80%, with no difference between cases with and without pEL2 (78% vs 85%; P = .08). The estimated 3-year FFR was 86%, with no difference between cases with and without pEL2 (81% vs 87%; P = .41). Four cases (3%) of EL2-related reinterventions were performed. In 65 cases (49%), aneurysm shrinkage was detected. pEL2 was an independent risk factor for absence of aneurysm shrinkage during follow-up (hazard ratio, 3.2; 95% CI, 1.2-8.3; P = .014). Patients without shrinkage had lower follow-up survival (64% vs 86% at 3-year; P = .009) and FFR (74% vs 90% at 3 years; P = .014) than patients with shrinkage. CONCLUSIONS: PEL2 is not infrequent (26%) after F/B-EVAR for J/P-AAAs and is correlated with preoperative antiplatelet therapy, aneurysm thrombus volume of ≤40%, and six or more patent sac afferent vessels. Patients with pEL2 have a diminished aneurysm shrinkage, which is correlated with lower follow-up survival and FFR compared with patients with aneurysm shrinkage.
引用
- Gallitto E, Faggioli GL, Campana F, et al. Type II endoleaks after fenestrated/branched endografting for juxtarenal and pararenal aortic aneurysms. J Vasc Surg. 2024. PMID: 38280685. doi:10.1016/j.jvs.2024.01.197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。